A. Sánchez-Guerrero

An Innovative Patient Stratification Tool Integrating Clinical and Economic Data for Benchmarking Oncology and Hematology Care: The PATONCOS System

Raquel Moreno-Díaz, Alejandra Melgarejo-Ortuño, Beatriz Monje-García, Laura Delgado-Téllez de Cepeda et autres

Background: The growing complexity and cost of oncohematological treatments has created an urgent need for standardized methodologies capable of enabling inter-institutional comparisons of healthcare expenditure within homogeneous patient groups. Cancer-related pharmaceutical costs vary substantially depending on tumour type, disease stage, and therapeutic …

es (code pays fourni par la source)

PATONCOS: A Novel Patient Stratification Tool Integrating Clinical and Economic Data for Benchmarking Oncology and Hematology Care

Raquel Moreno-Díaz, Alejandra Melgarejo-Ortuño, Beatriz Monje-García, Laura Delgado-Téllez de Cepeda et autres

Background:Advances in oncology have led to the development of novel targeted therapies with demonstrated efficacy in clinical trials; however, their real-world economic impact prior to and after market introduction remains insufficiently characterized [1,2]. Cancer-related healthcare costs vary significantly depending on disease stage, …

es (code pays fourni par la source)

Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

Carlos Taxonera, F. de Andrés-Nogales, Santiago García‐López, A. Sánchez-Guerrero et autres

BACKGROUND: To evaluate the cost-effectiveness of tofacitinib in comparison to vedolizumab for the treatment of moderate-to-severe ulcerative colitis (UC) after failure or intolerance to conventional therapy (bio-naive) or first-line biologic treatment (bio-experienced), from the Spanish National Health System (NHS) perspective. METHODS: A …

es (code pays fourni par la source)

PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

Luis A. Menchen, F. de Andrés-Nogales, A. Sánchez-Guerrero, B. Menchen et autres

es (code pays fourni par la source)

PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

Carlos Taxonera, F. de Andrés-Nogales, A. Sánchez-Guerrero, B. Menchen et autres

es (code pays fourni par la source)

Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy

María Esther Martínez-Muñoz, Rafael Forés, Ana Rodríguez‐Villa Lario, G. Bautista et autres

es (code pays fourni par la source)

2SPD-009 Implementation of a specific circuit of hazardous drugs in a pharmacy department

B Escudero-Vilaplana, Marta Manso-Manrique, Elena García-Sanz, Marina Calvo‐Salvador et autres

Background The National Institute for Occupational Safety and Health (NIOSH) published in 2016 a list of hazardous drugs (HDs) that, due to their harmful effects on the organism,?require special handling. While the preventive measures taken by health professionals in their preparation and …

es (code pays fourni par la source)

[Traceability of oncohematological drugs through data capture codes].

B Escudero-Vilaplana, Marta Manso-Manrique, Elena García-Sanz, A. Sánchez-Guerrero

es (code pays fourni par la source)

Conciliación de la medicación al ingreso y alta hospitalaria. Una experiencia consolidada

V Saavedra-Quirós, Esther Montero-Hernández, Belén Menchén-Viso, E. Santiago-Prieto et autres

es (code pays fourni par la source)

The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use

Julio Martínez-Cutillas, Carme Alerany-Pardo, Joaquín Borrás‐Blasco, Antonio Broto-Sumalla et autres

Rheumatoid arthritis (AR), psoriatic arthritis (PSA) and ankylosing spondylitis (AS) are autoimmune systemic diseases characterized by inflammation, pain and joint degeneration. The objective of this study is to evaluate, under the actual conditions of use, dosing patterns of adalimumab, etanercept, golimumab and …

es (code pays fourni par la source)

CP-047 Pharmacist’s contribution to the optimisation of drug therapy in oncology inpatients

J Ruiz-Gutierrez, V Alonso-Castro, BM Escudero Vilaplana, Aldara Martin-Alonso et autres

Background Numerous studies have shown that the presence of a pharmacist on hospital rounds as a full member of the patient care team prevents drug errors. Purpose To analyse pharmaceutical interventions made by a fourth-year pharmacy resident to optimise drug treatment in …

es (code pays fourni par la source)

CP-130 Analysis of the effectiveness and safety of infliximab in the treatment of psoriasis in a tertiary hospital

A De Rivas-Bravo, A Maestro-Nombela, E De la Piedra-Ríos, Aldara Martin-Alonso et autres

Background Psoriasis is an inflammatory skin disease characterised by increased cell signalling via cytokines and chemokines. A wide variety of treatment options are available including systemic biological treatments such as tumour necrosis factor antagonist infliximab. Purpose To evaluate the effectiveness and safety …

es (code pays fourni par la source)